AGE Key Statistics, Chart & Performance
The current stock price of AGE is 11.1 USD. In the past month the price decreased by -19.01%. In the past year, price decreased by -52.4%.
AGE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.37 | 390.24B | ||
| AMGN | AMGEN INC | 14.99 | 176.48B | ||
| GILD | GILEAD SCIENCES INC | 14.86 | 150.98B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.97 | 118.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.62 | 83.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 775.41 | 52.24B | ||
| INSM | INSMED INC | N/A | 37.10B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.22 | 27.55B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 21.65B |
Related stock screener links
About AGE
Company Profile
AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The company is headquartered in Alameda, California and currently employs 5 full-time employees. The company went IPO on 2018-11-29. The firm is focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The firm's proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows utilizing telomerase-expressing regenerative pluripotent stem cells (PSCs) for the manufacture of cell-based therapies. Its cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1. AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy comprised of young regenerative vascular-forming cells. AGEX-VASC1 may restore vascular support in aged ischemic tissues such as in peripheral vascular disease and ischemic heart disease.
Company Info
AGEX THERAPEUTICS INC
1101 Marina Village Parkway, Suite 201
Alameda CALIFORNIA 94501 US
CEO: Michael D. West
Employees: 5
Phone: 15106718370
AGEX THERAPEUTICS INC / AGE FAQ
Can you describe the business of AGEX THERAPEUTICS INC?
AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The company is headquartered in Alameda, California and currently employs 5 full-time employees. The company went IPO on 2018-11-29. The firm is focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The firm's proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows utilizing telomerase-expressing regenerative pluripotent stem cells (PSCs) for the manufacture of cell-based therapies. Its cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1. AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy comprised of young regenerative vascular-forming cells. AGEX-VASC1 may restore vascular support in aged ischemic tissues such as in peripheral vascular disease and ischemic heart disease.
Can you provide the latest stock price for AGEX THERAPEUTICS INC?
The current stock price of AGE is 11.1 USD. The price decreased by -11.9% in the last trading session.
Does AGE stock pay dividends?
AGE does not pay a dividend.
What is the ChartMill technical and fundamental rating of AGE stock?
AGE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the employee count for AGE stock?
AGEX THERAPEUTICS INC (AGE) currently has 5 employees.
What is the next earnings date for AGE stock?
AGEX THERAPEUTICS INC (AGE) will report earnings on 2024-05-13, after the market close.
AGE Technical Analysis
AGE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AGE. AGE may be in some trouble as it scores bad on both profitability and health.
AGE Financial Highlights
Over the last trailing twelve months AGE reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS decreased by -42.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -115.07% | ||
| ROE | -166.86% | ||
| Debt/Equity | 0.08 |